Neurothera Labs Inc.
NTLX.V
TSX
| 12/31/2025 | 09/30/2025 | 12/31/2024 | |||
|---|---|---|---|---|---|
| Revenue | 159.00K | 236.00K | 206.00K | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | 159.00K | 236.00K | 206.00K | ||
| Cost of Revenue | 54.00K | 70.00K | 343.00K | ||
| Gross Profit | 105.00K | 166.00K | -137.00K | ||
| SG&A Expenses | 777.00K | 260.00K | 305.00K | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 2.63M | 330.00K | 2.36M | ||
| Operating Income | -2.47M | -94.00K | -2.15M | ||
| Income Before Tax | -4.08M | -94.00K | -3.47M | ||
| Income Tax Expenses | 19.00K | -- | 5.00K | ||
| Earnings from Continuing Operations | -4.10M | -94.00K | -3.48M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | 240.00K | -- | 1.19M | ||
| Net Income | -3.86M | -94.00K | -2.29M | ||
| EBIT | -2.47M | -94.00K | -2.15M | ||
| EBITDA | -2.42M | -46.00K | -2.06M | ||
| EPS Basic | -0.05 | -0.04 | -0.04 | ||
| Normalized Basic EPS | -0.03 | -- | 0.00 | ||
| EPS Diluted | -0.05 | -0.04 | -0.04 | ||
| Normalized Diluted EPS | -0.03 | -- | 0.00 | ||
| Average Basic Shares Outstanding | 84.90M | -- | 63.30M | ||
| Average Diluted Shares Outstanding | 84.90M | 63.30M | 63.30M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||